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Background: Systemic chemotherapy in the adjuvant setting can cure breast cancer in some patients that would
otherwise recur with incurable, metastatic disease. However, since only a fraction of patients would have recurrence
after surgery alone, the challenge is to stratify high-risk patients (who stand to benefit from systemic
chemotherapy) from low-risk patients (who can safely be spared treatment related toxicities and costs).
Methods: We focus here on risk stratification in node-negative, ER-positive, HER2-negative breast cancer. We use a
large database of publicly available microarray datasets to build a random forests classifier and develop a robust
multi-gene mRNA transcription-based predictor of relapse free survival at 10 years, which we call the Random
Forests Relapse Score (RFRS). Performance was assessed by internal cross-validation, multiple independent data sets,
and comparison to existing algorithms using receiver-operating characteristic and Kaplan-Meier survival analysis.
Internal redundancy of features was determined using k-means clustering to define optimal signatures with smaller
numbers of primary genes, each with multiple alternates.
Results: Internal OOB cross-validation for the initial (full-gene-set) model on training data reported an ROC AUC of
0.704, which was comparable to or better than those reported previously or obtained by applying existing methods
to our dataset. Three risk groups with probability cutoffs for low, intermediate, and high-risk were defined. Survival
analysis determined a highly significant difference in relapse rate between these risk groups. Validation of the
models against independent test datasets showed highly similar results. Smaller 17-gene and 8-gene optimized
models were also developed with minimal reduction in performance. Furthermore, the signature was shown to be
almost equally effective on both hormone-treated and untreated patients.
Conclusions: RFRS allows flexibility in both the number and identity of genes utilized from thousands to as few as
17 or eight genes, each with multiple alternatives. The RFRS reports a probability score strongly correlated with risk
of relapse. This score could therefore be used to assign systemic chemotherapy specifically to those high-risk
patients most likely to benefit from further treatment.Background
Large randomized trials have shown that chemotherapy
administered in the perioperative setting (for example,
adjuvant chemotherapy) can cure patients otherwise des-
tined to recur with systemic, incurable cancer [1]. Once* Correspondence: obigriffith@wustl.edu; spellmap@ohsu.edu; grayjo@ohsu.edu
1Department of Cancer and DNA Damage Responses, Life Sciences Division,
Lawrence Berkeley National Laboratory, One Cyclotron Rd, Berkeley
94720, CA, USA
6Current affiliation: Department of Molecular and Medical Genetics, Oregon
Health and Science University, 3181 SW Sam Jackson Park Rd, Portland
97239, OR, USA
Full list of author information is available at the end of the article
© 2013 Griffith et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthis recurrence has happened, the same chemotherapy is
never curative. Therefore, the adjuvant window is a pri-
vileged period of time, when the decision to administer
additional therapy or not, as well as the type, duration,
and intensity of such therapy takes center stage. Node-
negative, ER-positive, HER2-negative breast cancer
patients have a favorable prognosis when treated with
adjuvant hormonal therapy only, but a fraction of such
patients recur locally or systemically. Most patients are
currently treated not only with hormonal therapy but
also cytotoxic chemotherapy, even though it is prob-
ably unnecessary for most [1,2]. Our goal was to strat-
ify these patients with respect to the likelihood ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proaches to this problem were developed using rela-
tively small datasets. Here we have explored the extent
to which larger and more current meta-datasets can be
used to improve predictor performance. Our approach
was to develop a multi-gene transcription-level-based
classifier of 10-year-relapse (disease recurrence within
10 years) using a large database of existing, publicly
available microarray datasets. Existing solutions have
been implemented on costly platforms that are slow to
return results to the patient. However, new assay
technologies exist which could make breast cancer
prognostics much more accessible and timely. Some of
these potential assay technologies can only measure
transcription of a relatively small number of genes
while still optimizing cost and efficiency. To this end,
we developed a robust prognostic panel offering flexi-
bility in both the number and identity of genes utilized
from thousands to as few as eight genes, each with
multiple alternatives to maximize the chance of suc-
cessful migration to other assay technologies.
Methods
Literature search and curation
Studies were collected which provided gene expression
data for ER+, LN-, HER2- patients with no systemic
chemotherapy (hormonal therapy was allowed). Each
study was required to have a sample size of at least 100,
report LN status, and include time and events for either
recurrence-free survival or distant metastasis-free sur-
vival. The latter were grouped together for survival
analysis where all events represent either a local orFigure 1 Duplicate analysis showing approximate relationship betw
approximate overlap between GEO datasets used in the current study. T
significant overlap.distant relapse of disease. If ER or HER2 status were not
reported, they were determined by array, but preference
was given to studies with clinical determination first. A
minimum of 10 years follow-up was required for train-
ing the classifier. However, patients with shorter follow-
up were included in survival analyses. Patients with
immediately postoperative events (time = 0) were ex-
cluded. Nine studies [3–11] meeting the above criteria
were identified by searching PubMed and the Gene
Expression Omnibus (GEO) database [12]. To allow
combination of the largest number of samples, only the
common Affymetrix U133A gene expression platform
was used. A total of 2,175 breast cancer samples were
identified. After filtering for only those samples which
were ER+, node-negative, and had not received systemic
chemotherapy, 1,403 samples remained. Duplicate ana-
lysis removed a further 405 samples due to the signifi-
cant amount of redundancy between studies (Figure 1).
Filtering for ER + and HER2- status using array determi-
nations eliminated another 140 samples (51 ER-, 72
HER2+, 17 ER-/HER2+, Additional file 1: Figure S1).
Some ER- samples were from the Schmidt (2008) dataset
(31/201) which did not provide clinical ER status and
thus for that study we relied solely on arrays for deter-
mination of ER status. However, there were also a small
number (37/760) from the remaining studies, which rep-
resent discrepancies between array status and clinical
determination. In such cases, both the clinical and array-
based determinations were required to be positive for in-
clusion in further analysis. A total of 858 samples passed
all filtering steps including 487 samples with 10-year
follow-up data (213 relapse; 274 no relapse). Theeen studies in analysis. The VennMaster diagram shows the
hree studies show zero overlap while the other six show
Griffith et al. Genome Medicine 2013, 5:92 Page 3 of 14
http://genomemedicine.com/content/5/10/92remaining 371 samples had insufficient follow-up for
10-year classification analysis but were retained for use
in survival analysis. None of the 858 samples were
treated with systemic chemotherapy but 302 (35.2%)
were treated with adjuvant hormonal therapy of which
95.4% were listed as tamoxifen. The 858 samples were
broken into two-thirds training and one-third testing
sets resulting in: a training set of 572 samples for use in
survival analysis and 325 samples with 10 year-follow-
up (143 relapse; 182 no relapse) for classification ana-
lysis; and a testing set of 286 samples for use in survival
analysis and 162 samples with 10-year follow-up (70
relapse; 92 no relapse) for classification analysis. The
numbers of samples available for classification analysis
and survival analysis differed because the former was
performed only on those samples that could be binarized
into ‘relapse’ or ‘no relapse’ with 10 years of follow-up
whereas the latter made use of all patients (with censor-
ing), even those with no relapse but <10 years follow-
up. Table 1 outlines the datasets used in the analysis
and Figure 2 illustrates the breakdown of samples for
analysis.
Preprocessing
All data processing and analyses were completed with
open source R/Bioconductor packages. Raw data (Cel
files) were downloaded from GEO. Duplicate samples
were identified and removed if they had the same data-
base identifier (for example, GSM accession), same sam-
ple/patient ID, or showed a high correlation (r >0.99)
compared to any other sample in the dataset. Raw data
were normalized and summarized using the affy [13]
and gcrma [14] packages in R/Bioconductor. Probe sets
were mapped to Entrez gene symbols using both stand-
ard and custom annotation files [15]. ER and HER2 ex-




Desmedt, 2007 [3] GSE7390 198 135
Ivshina, 2006 [4] GSE4922 290 133
Loi, 2007 [5] GSE6532 327 170
Miller, 2005 [6] GSE3494 251 132
Schmidt, 2008 [7] GSE11121 200 200b
Sotiriou, 2006 [8] GSE2990 189 113
Symmans, 2010 [9] GSE17705 298 175
Wang, 2005 [10] GSE2034 286 209
Zhang, 2009 [11] GSE12093 136 136
Nine studies 2,175 1403
aUntreated includes some patients with adjuvant endocrine therapy alone or radiat
bER status not available, filtered later based on array expression data.sets. For the Affymetrix U133A array we and others have
found the probe set ‘205225_at’ to be most effective for
determining ER status [16]. The rank sum of the best
probe sets for ERBB2 (216835_s_at), GRB7 (210761_s_at),
STARD3 (202991_at), and PGAP3 (55616_at) was used to
determine HER2 amplification status. This was calculated
by taking the sum of individual expression level ranks of
each of the four probes. Cutoff values for ER and HER2 sta-
tus were chosen by mixed model clustering (mclust [17,18]
package). Mclust performs normal mixture modeling, fitted
via an expectation maximization algorithm. A mixture
model is a probabilistic model for representing the presence
of subpopulations within an overall population. In this case
we hypothesized that two populations exist in the dataset
(ER + and ER- or HER2+ and HER2-) and would be repre-
sented by two distinct distributions of expression values.
This is clearly visible in Additional file 1: Figure S1 where
both ER and HER2 expression levels apparently manifest as
two distinct distributions. In both cases, mclust successfully
identified two distributions and we used the maximum
value of the first distribution as an unbiased, objective cut-
off to separate the two distributions. Unsupervised cluster-
ing was performed to assess the extent of batch effects.
Once all prefiltering was complete, data were randomly
split into training (two-thirds) and test (one-thirds) datasets
while balancing for study of origin and number of relapses
with 10-year follow-up. The test dataset was renormalized,
put aside, left untouched, and only used for final validation,
once each for the full-gene, 17-gene, and eight-gene classi-
fiers. Training data was renormalized together as above.
Probe sets were then filtered for a minimum of 20% sam-
ples with expression above background threshold (raw
value >100) and coefficient of variation (COV) between 0.7
and 10. A total of 3,048 probe sets/genes passed this filter-
ing and formed the basis for the ‘full-gene-set’ model de-






135 116 42 60
2 2 0 2
43 40 10 5
115 100 30 52
200 155 25 46
48 45 12 15
110 102 12 41
209 173 67 29
136 125 15 24
998 858 213 274
ion.
Figure 2 Sample breakdown. A total of 858 samples passed all filtering steps including 487 samples with 10-year follow-up data (213 relapse;
274 no relapse). The remaining 371 samples had insufficient follow-up for 10-year classification analysis but were retained for use in survival
analysis. The 858 samples were broken into two-thirds training and one-third testing sets resulting in: a training set of 572 samples for use in
survival analysis and 325 samples with 10-year follow-up (143 relapse; 182 no relapse) for classification analysis; and a testing set of 286 samples
for use in survival analysis and 162 samples with 10-year follow-up (70 relapse; 92 no relapse) for classification analysis.
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percent expression and COV) are provided as Additional
files 2, 3, 4, and 5.
Classification (training)
Classification was performed on only training samples
with either a relapse or no relapse after 10-year follow-
up using the randomForest [19] package. Forests were
created with at least 100,001 trees (odd number ensures
fully deterministic model) and otherwise default settings.
Performance was assessed by area under the curve
(AUC) of a receiver-operating characteristic (ROC)
curve, calculated with the ‘ROCR’ package, from Ran-
dom Forests internal out-of-bag (OOB) testing results.
In Random Forests, this OOB testing takes the place of
cross-validation to get an unbiased estimate of the test
set error. Each tree is constructed using a different ran-
dom bootstrap sample of about two-thirds of cases from
the original data. Each case left out in the construction
of the tree is run through that tree to get a classification.
In this way, a test set classification is obtained for each
case in about one-third of the trees. At the end of the
run, the software takes j to be the class that got the most
votes every time case n was OOB. The proportion of
times that j is not equal to the true class of n averaged
over all cases is the OOB error estimate. By default, RF
performs a binary classification (for example, relapse
versus no relapse). However it also reports a probability(proportion of ‘votes’) for relapse, which we call the
Random Forests Relapse Score (RFRS). Risk group
thresholds were determined from the distribution of re-
lapse probabilities using mixed model clustering to set
cutoffs for low, intermediate, and high-risk groups.
Determination of optimal 17-gene and eight-gene sets
Initially an optimal set of 20 genes was selected by re-
moving redundant probe sets and extracting the top 100
genes (by reported Gini variable importance), k-means
clustering (k = 20) these genes and selecting the best
gene from each cluster (again by variable importance)
(Figure 3). Additional genes in each cluster will serve as
robust alternates in case of failure to migrate primary
genes to an assay platform. A gene might fail to migrate
due to problems with prober/primer design or differ-
ences in the sensitivity of a specific assay for that gene.
The top 100 genes/probe sets were also manually
checked for sequence correctness by alignment to the
reference genome (see Additional file 6). Seven genes/
probe sets with ambiguous or erroneous alignments
were excluded. Three genes/probe sets were also ex-
cluded because of their status as hypothetical proteins
(KIAA0101, KIAA0776, KIAA1467). After these re-
movals, three clusters were lost, leaving a set of 17 pri-
mary genes and 73 alternate genes. All but two primary
genes have two or more alternates (TXNIP is without al-
ternate, and APOC1 has a single alternate). Table 2 lists
Figure 3 Heatmap showing top 100 probe sets after k-means clustering (k = 20). Training data (n = 325) were clustered by expression value
using k-means clustering (k = 20) for the top 100 probe sets identified by random forest classification variable importance. The first color side bar
on the left indicates cluster number and the second indicates relative variable importance within the cluster (darker blue = greater importance).
The top side bars indicate risk group (low, intermediate, and high from left to right) and relapse status (red = relapse; yellow = no relapse). Genes
(probe sets) are indicated on the right axis. Genes highlighted in yellow represent the primary genes in the model (best in each cluster). Genes
not highlighted represent alternates to primary genes in each cluster. Genes highlighted in pink represent genes excluded from the model
because of probe set sequence ambiguity or status as a hypothetical protein.
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available) and their variable importance values (See
Additional file 1: Table S1 for complete list). The above
procedure was repeated to produce an optimal set of eight
genes, this time starting from the top 90 non-redundant
probe sets (excluding the 10 genes with problems identi-
fied above), k-means clustering (k = 8) these genes andselecting the best gene from each cluster (Additional
file 1: Figure S2). All eight genes were also included in
the 17-gene set and have at least two alternates (Table 3,
Additional file 1: Table S2). Using the final optimized
17-gene and eight-gene sets as input, new RF models
were built on training data. Actual probe sequences for
the top 100 probe sets are provided in Additional file 7.
Table 2 The 17-gene RFRS signature
Primary predictor Alternate 1 Alternate 2
CCNB2 0.785 MELK 0.739 GINS1 0.476
TOP2A 0.590 MCM2 0.428 CDK1 0.379
RACGAP1 0.588 LSM1 0.139 SCD 0.125
CKS2 0.515 NUSAP1 0.491 ZWINT 0.272
AURKA 0.508 PRC1 0.499 CENPF 0.306
FEN1 0.403 FADD 0.313 SMC4 0.170
EBP 0.341 RFC4 0.264 NCAPG 0.234
TXNIP 0.292 N/A N/A N/A N/A
SYNE2 0.270 SCARB2 0.225 PDLIM5 0.167
DICER1 0.209 CALD1 0.129 SOX9 0.125
AP1AR 0.201 PBX2 0.134 WASL 0.126
NUP107 0.197 FAM38A 0.165 PLIN2 0.110
APOC1 0.176 APOE 0.121 N/A N/A
DTX4 0.164 AQP1 0.141 LMO4 0.120
FMOD 0.154 RGS5 0.120 PIK3R1 0.103
MAPKAPK2 0.151 MTUS1 0.136 DHX9 0.136
SUPT4H1 0.111 PHB 0.106 CD44 0.105
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Survival analysis on all training data, now also including
those patients with <10 years of follow-up, was performed
with risk group as a factor, for the full-gene, 17-gene, and
eight-gene models, using the ‘survival’ package. Note, the
risk scores and groups for samples used in training were
assigned from internal OOB cross-validation. Only those
patients not used in initial training (without 10-year
follow-up) were assigned a risk score and group by de
novo classification. Significance between risk groups was
determined by Kaplan-Meier log rank test (with test for
linear trend). To directly compare relapse rates at 10 years
for each risk group to that reported in the OncotypeDX
publication [20], the overall relapse rates in our patient
cohort were randomly down-sampled to the same rate
(15%) as in their cohort [20] and results averaged >1,000
iterations. To illustrate, the training dataset includes 572Table 3 The eight-gene RFRS signature
Primary predictor Alternate 1 Alternate 2
CCNB2 0.785 MELK 0.739 TOP2A 0.590
RACGAP1 0.588 TXNIP 0.292 APOC1 0.176
CKS2 0.515 NUSAP1 0.491 FEN1 0.403
AURKA 0.508 PRC1 0.499 CENPF 0.306
EBP 0.341 FADD 0.313 RFC4 0.264
SYNE2 0.270 SCARB2 0.225 PDLIM5 0.167
DICER1 0.209 FAM38A 0.165 FMOD 0.154
AP1AR 0.201 MAPKAPK2 0.151 MTUS1 0.136samples with 143 relapse events (that is, 25.0% relapse
rate). Samples with relapse events were randomly elim-
inated from the cohort until only 15% of remaining
samples had relapse events (76/505 = 15%). This ‘down-
sampled’ dataset was then classified using the RFRS model
to assign each sample to a risk group and the rates of
relapse determined for each group. The entire down-
sampling procedure was then repeated 1,000 times to
obtain average estimated rates of relapse for each risk
group given the overall rate of relapse of 15%. Setting
the overall relapse rate to 15% is also useful because
this more closely mirrors the general population rate
of relapse. Without this down-sampling, expected relapse
rates in each risk group would appear unrealistically high.
See Figure 2 for explanation of the breakdown of samples
into training and test sets used for classifier building and
survival analysis.
Next, the full-gene, 17-gene, and eight-gene RF models
along with risk group cutoffs were applied to the inde-
pendent test data. The same performance metrics, sur-
vival analysis, and estimates of 10-year relapse rates
were performed as above. The 17-gene model was also
tested on the independent test data, stratified by treat-
ment (untreated vs. hormone therapy treated), to evalu-
ate whether performance of the signature was biased
towards one patient subpopulation or the other. Finally,
for direct performance comparison on the same datasets,
the Oncotype DX algorithm [20] was implemented in R
and applied to both training and test datasets.
The independent test data were not used in any way
during the training phase. However, these samples repre-
sent a random subset of the same overall patient popula-
tions that were used in training. Therefore, they are not
as fully independent as recommended by the Institute of
Medicine ‘committee on the review of omics-based tests
for predicting patient outcomes in clinical trials’ [21].
Therefore, additional independent validations were per-
formed against the NKI dataset [22] obtained from the
Netherlands Cancer Institute [23] and the METABRIC
dataset [24] accessed through Synapse [25]. The NKI
data represent a set of 295 consecutive patients with pri-
mary stage I or II breast carcinomas. The dataset was fil-
tered down to the 89 patients who were node-negative,
ER-positive, HER2-negative, and not treated by systemic
chemotherapy. Relapse times and events were defined by
any of distant metastasis, regional recurrence or local re-
currence. The METABRIC data represent a set of 1,992
primary breast tumors. The dataset was filtered down to
the 315 patients who were node-negative, ER-positive,
HER2-negative, and not treated by systemic chemother-
apy. Relapse times and events were used as provided. Ex-
pression values from the NKI Agilent array data and
METABRIC (Illumina HT 12v3) array were rescaled to
the same distribution as that used in training using the
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17-gene-set RFRS models were extracted for further ana-
lysis. If more than one Agilent or Illumina probe set
could be mapped to an RFRS gene then the probe set
with best performance was used. The full-gene-set
model was not applied because not all Affymetrix-
defined genes (probe sets) in the full-gene-set could be
mapped to Agilent or Illumina-defined genes (probe
sets). However, the 17-gene and eight-gene RFRS models
were applied to NKI and METABRIC data to calculate
predicted probabilities of relapse. Patients were divided
into low-, intermediate-, and high-risk groups by ranking
according to probability of relapse and then dividing so
that the proportions in each risk group were identical to
that observed in training. ROC AUC, survival P values,
and estimated rates of relapse were then calculated as
above. It should be noted that while the NKI clinical
data described here (n = 89) had an average follow-up
time of 9.55 years (excluding relapse events), 34 patients
had a follow-up time of <10 years without an event
(range, 1.78-9.83 years). Similarly, the METABRIC clin-
ical data (n = 315) had an average follow-up time of
9.85 years (excluding relapse events) but 118 patients
had a follow-up time of <10 years without an event
(range, 0.05-9.80 years). These patients with <10 years of
follow-up but no events would not have met our criteria
for inclusion in the training dataset and likely include
some events which have not occurred yet. If anything,
this is likely to reduce the AUC estimate and underesti-
mate P value significance in survival analysis.
Selection of reference genes
While not necessary for Affymetrix, migration to other
assay technologies (for example, RT-PCR approaches)
may require highly and invariantly expressed genes to
act as a reference for determining accurate gene expres-
sion level estimates. To this end, we developed two sets
of reference genes. The first was chosen by the following
criteria: (1) filtered if not expressed above background
threshold (raw value >100) in 99% of samples; (2) filtered
if not in top fifth percentile (overall) for mean expres-
sion; (3) filtered if not in top 10th percentile (remaining
genes) for standard deviation; (4) ranked by coefficient
of variation. The top 25 reference genes are listed in
Additional file 1: Table S3 along with reference genes
used by OncotypeDX. The second set of reference genes
were chosen to represent three ranges of mean expres-
sion levels encompassed by genes in the 17-gene signa-
ture (low, 0-400; medium, 500-900; high, 1,200-1,600).
For each mean expression range, genes were: (1) fil-
tered if not expressed above background threshold
(raw value >100) in 99% of samples; and (2) ranked by
coefficient of variation. The top five genes from each
range are listed in Additional file 1: Table S4. Referencegenes underwent the same manual checks for sequence
correctness by alignment to the reference genome as
above (see Additional file 8). Five genes were marked
for exclusion in the first set and three genes excluded
from the second set. Actual probe sequences for all ref-
erence probe sets are provided in Additional file 9.
Implementation of algorithm
The RFRS algorithm is implemented in the R programming
language and can be applied to independent patient data.
Input data are tab-delimited text files of normalized expres-
sion values with 17 or eight transcripts/genes as columns
and patient(s) as rows. A sample patient data file (patient_-
data.txt) is presented in Additional file 10. A sample R pro-
gram (RFRS_sample_code.R) for running the algorithm is
presented in Additional file 10. The RFRS algorithm con-
sists of a Random Forest of 100,001 decision trees. This is
precomputed, provided as an R data object (see Additional
file 11) and must be included in the working directory.
Each node (branch) in each tree represents a binary deci-
sion based on transcript levels for transcripts described
above. Based on these decisions, the patient is assigned to a
terminal leaf of each decision tree, representing a vote for
either ‘relapse’ or ‘no relapse’. The fraction of votes for
‘relapse’ to votes for ‘no relapse’ represents the RFRS - a
measure of the probability of relapse. If RFRS is ≥0.606
the patient is assigned to the ‘high-risk’ group, if ≥0.333
and <0.606 the patient is assigned to the ’intermediate-risk’
group, and if <0.333 the patient is assigned to the ‘low-risk’
group. These cutoffs were chosen by mixed-model cluster-
ing during the training phase. The patient’s RFRS value is
also used to determine a likelihood of relapse by compari-
son to a loess fit of RFRS versus likelihood of relapse for the
training dataset. Precomputed R data objects for the loess
fit (RelapseProbabilityFit.Rdata) and summary plot (Relap-
seProbabilityPlot.Rdata) are loaded from file (see Additional
file 12). The patient’s estimated likelihood of relapse is
determined, added to the summary plot, and output as a
new report (see Additional file 13). A complete list of GEO
sample identifiers, used for training and testing (Additional
file 14), and additional sample R code (Additional file
15), are provided to help others reproduce the RFRS
implementation.
Results and discussion
Internal OOB cross-validation for the initial (full-gene-
set) model on training data reported an ROC AUC of
0.704. This was comparable or better than those re-
ported by Johannes et al. (2010) who tested a number
of different classifiers on a smaller subset of the same
data and found AUCs of 0.559 to 0.671 [26]. It also
compares favorably to the AUC value of 0.688 when
the OncotypeDX algorithm was applied to this same
training dataset.
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groups with probabilities for low-risk <0.333; intermediate-
risk 0.333-0.606; and high-risk ≥0.606 (Figure 4). Survival
analysis determined a highly significant difference in relapse
rate between risk groups (P = 3.95E-11; Figure 5A). After
down-sampling to a 15% overall rate of relapse, approxi-
mately 46.7% (n = 235) of patients were placed in the low-
risk group and were found to have a 10-year risk of relapse
of only 8.0%. Similarly, 38.6% (n = 195) and 14.9% (n = 75)
of patients were placed in the intermediate- and high-risk
groups with rates of relapse of 17.6% and 30.3%, re-
spectively. These results are very similar to those for
OncotypeDX which were reported as 51% of patients
in the low-risk category with a rate of distant recur-
rence at 10 years of 6.8% (95% CI, 4.0-9.6); 22% in
intermediate-risk category with recurrence rate of
14.3% (95% CI, 8.3-20.3); and 27% in high-risk category
with recurrence rate of 30.5% (95% CI, 23.6-37.4) [20].
Our goal was to identify a potential signature for mi-
gration to a more affordable and faster platform. We can
expect a certain amount of attrition when migrating to
such platforms. Therefore we developed a rational ap-
proach in which approximately 100 candidate signature
genes were identified but organized into signatures of
eight- and 17-gene sets with each gene having multiple
alternates in case of platform migration failures. The sig-
nature sizes were chosen for practical reasons, with theFigure 4 Risk group threshold determination. The distribution of RFRS
comparing those with a known relapse (right side; in blue) versus those wit
known relapse tend to have a higher predicted likelihood of relapse (by RF
thresholds (0.333 and 0.606) for defining low-, intermediate-, and high-riskassumption that high-throughput, low-cost platforms
may have limitations to approximately 10 or 20 features
and need space for one or more control/reference genes.
Validation of the models against the independent test
dataset also showed very similar results to training esti-
mates. The full-gene-set model had an AUC of 0.730
and the 17-gene and eight-gene optimized models had
minimal reduction in performance with AUC of 0.715
and 0.690, respectively. Again, this compared favorably
to the AUC value of 0.712 when the OncotypeDX algo-
rithm was applied to the same test dataset. Survival ana-
lysis again found very significant differences between the
risk groups for the full-gene (P = 6.54E-06), 17-gene (P =
9.57E-06), and eight-gene (P = 2.84E-05; Figure 5B)
models. For the 17-gene model, approximately 38.2%
(n = 97) of patients were placed in the low-risk group
and were found to have a 10-year risk of relapse of only
7.8%. Similarly, 40.5% (n = 103) and 21.3% (n = 54) of pa-
tients were placed in the intermediate and high-risk
groups with rates of relapse of 15.3% and 26.8%, respect-
ively. Very similar results were observed for the full-
gene and eight-gene models (Table 4). We have also
compared performance to random gene sets of the same
sizes (that is, eight- and 17-gene sets). Genes were
chosen randomly from the total set of 3,048 genes which
passed basic percent expression and COV filtering. On
average, AUC values of 0.649 and 0.608 were estimatedscores was determined for patients in the training dataset (n = 325)
h no known relapse (left side; in red). As expected, patients without a
RS) and vice versa. Mixed model clustering was used to identify
groups as indicated.
Figure 5 Likelihood of relapse according to RFRS group. Kaplan-Meier survival analysis shows a significant difference in relapse-free survival
for low-, intermediate-, and high-risk groups as defined by: (A) the full-gene-set model on training data (n = 572, P = 3.95E-11); (B) the eight-gene-
set model on independent test data (n = 286, P = 2.84E-05); (C) the eight-gene-set model on independent NKI data (n = 89, P = 0.004); (D) the
17-gene-set model on independent METABRIC data (n = 315, P <1.99E-04). Note, for panel A, the risk scores and corresponding groups for samples
used in classifier training (n = 325) were assigned from internal OOB cross-validation. Only those patients not used in initial training (training data
without 10-year follow-up; test data) were assigned a risk score and group by de novo classification. Significance between risk groups was determined
by Kaplan-Meier log rank test (with test for linear trend).
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http://genomemedicine.com/content/5/10/92for random sets of 17 and eight genes compared to
0.715 and 0.690 for RFRS gene sets on the same inde-
pendent test dataset. Only 2.2% of 17-gene and 3.6% of
eight-gene random sets performed as well as those we
chose. AURKA alone had an AUC of 0.623.
Validation against the additional, independent, NKI
dataset also had very similar results. The 17-gene andeight-gene models had AUC values of 0.688 and 0.699,
respectively, nearly identical to the results for the
previous independent dataset. Differences between risk
groups in survival analysis were also significant for both
17-gene (P = 0.023) and eight-gene (P = 0.004, Figure 5C)
models. Similar results were also obtained from the val-
idation against METABRIC data with 17-gene (AUC =
Table 4 Comparison of validation results in independent test data for full-gene-set, 17-gene, and eight-gene
RFRS models
Relapse-free survival
RFRS performance Low risk Intermediate risk High risk
Model AUC RR n (%) RR n (%) RR n (%) KM (P)
Full-gene-set 0.730 6.9 78 (30.7) 15.8 133 (52.4) 26.8 43 (16.9) 6.54E-06
17-gene 0.715 7.8 97 (38.2) 15.3 103 (40.5) 26.8 54 (21.3) 9.57E-06
Eight-gene 0.690 9.7 101 (39.8) 13.9 105 (41.3) 28.3 48 (18.9) 2.84E-05
KM (P), p-value for Kaplan-Meier logrank test (with test for linear trend) from survival analysis; RR, relapse rate.
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http://genomemedicine.com/content/5/10/920.628, P <1.99E-04, Figure 5D) and eight-gene models
(AUC = 0.642, P <0.04). It should be noted that any level
of performance observed on independent test datasets is
somewhat disadvantaged if they make use of different
expression platforms (as NKI and METABRIC datasets
do). Even with renormalizing or rescaling, the cutoffs
and inter-variable relationships will likely be sensitive to
changes in the inherent distribution and dynamic range
that accompany another technology. When migrating to
a new platform, an additional training phase should be
performed. Our signatures and their alternates provide a
convenient candidate list for development on such a
new platform.
The trend between risk group and rate of relapse



























Figure 6 Estimated likelihood of relapse at 10 years for any RFRS valu
(n = 505) for 50 RFRS intervals (from 0 to 1). A smooth curve was fitted usin
the error in the fit. Short vertical marks just above the x axis, one for each p
training data. Thresholds for risk groups are indicated. The plot shows a lin
with the likelihood ranging from approximately 0 to 40%.training data) into five equal groups instead of the three
groups defined above (Additional file 1: Figure S4). This
observation is consistent with the idea that the RFRS is a
quantitative, linear measure directly related to probabil-
ity of relapse. Figure 6 shows the likelihood of relapse at
10 years, calculated for 50 RFRS intervals (from 0 to 1),
with a smooth curve fitted, using a loess function and
95% confidence intervals representing error in the fit.
The distribution of RFRS values observed in the training
data is represented by short vertical marks just above
the x axis, one for each patient. From this training data
we can estimate that 18.9% of patients from a population
with an overall 15% relapse rate will be predicted to have
a 5% or lower risk of relapse. Similarly, 37.0% will have a
10% or lower risk of relapse.0.6 0.8 1.0
elapse Score (RFRS)
ediate High
e. The likelihood of relapse was calculated in the training dataset
g a loess function and 95% confidence intervals plotted to represent
atient, represent the distribution of RFRS values observed in the
ear relationship between RFRS and likelihood of relapse at 10 years
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http://genomemedicine.com/content/5/10/92In order to maximize the total size of our training
dataset we allowed samples to be included from both
untreated patients and those who received adjuvant hor-
monal therapy such as tamoxifen. Since outcomes likely
differ between these two groups, and they may represent
fundamentally different subpopulations, it is possible
that performance of our predictive signatures is biased
towards one group or the other. To assess this issue we
performed validation against the independent test data-
set, stratified by treatment status, using the 17-gene
model. Both groups were found to have comparable
AUC values with the slightly better value of 0.740 for
hormone-treated versus 0.709 for untreated. Survival
curves were also highly similar and significant with P
value of 0.004 and 3.76E-07 for treated and untreated re-
spectively (Additional file 1: Figure S5A and S5B). The
difference in P value appears more likely due to differ-
ences in the respective sample sizes than actual differ-
ence in survival curves. This is important because it
predicts equal or better performance of the signature in
hormonal-therapy treated patients.
Several prognostic signatures in breast cancer identify
the same or very similar risk groups of patients [27,28].
While the genes utilized in the RFRS model have onlyFigure 7 Gene Ontology categorization of 17-gene model. A Gene On
associated GO biological processes for the 17-gene model. A VennMaster d
simplify, redundant terms were grouped together. Genes in the 17-gene lis
involved in breast cancer biology including cell cycle, hormone response, c
others. Since the eight-gene set is entirely contained in the 17-gene set itminimal overlap with those identified in other breast
cancer outcome signatures (Additional file 1: Figure S6),
the prognostic ability of the RFRS model compares well
with other assays. The 17-gene and eight-gene optimized
sets have only a single gene (AURKA) in common with
OncotypeDX [20], a single gene in common with
Veridex [10] (FEN1, 17-gene set only), and none with
Mammaprint [22]. The similar level of performance be-
tween our signature and others together with the lack of
overlap in gene members suggests that there are many
equivalent solutions to this problem. We provide an op-
timal subset for our training data but acknowledge that
many other effective subsets are also possible and pro-
vide a method for identifying such combinations via the
predictor alternates derived from k-mean clustering ana-
lysis. Gene Ontology categorization was performed using
DAVID [29,30] and revealed that genes in the 17-gene
list are involved in a wide range of biological processes
known to be involved in breast cancer biology including
cell cycle, hormone response, cell death, DNA repair,
transcription regulation, wound healing, and others
(Figure 7). Since the eight-gene set is entirely contained
in the 17-gene set it would be involved in many of the
same processes. GO categorization of the 17-gene settology (GO) categorization was performed using DAVID to identify the
iagram represents the approximate overlap between GO terms. To
t are involved in a wide range of biological processes known to be
ell death, DNA repair, transcription regulation, wound healing, and
would be involved in many of the same processes.
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http://genomemedicine.com/content/5/10/92was provided to characterize this specific set of genes.
However, when training our models, we required only
that the chosen genes/probes be robustly and reprodu-
cibly predictive of relapse. We did not require the signa-
tures to be a comprehensive list of such correlated
genes/probes. In fact, we show that there are likely many
essentially equivalent subsets of genes that would work
equally well as predictors of outcome. For practical rea-
sons we have attempted to choose a relatively small list
of genes to facilitate migration to other technologies.
With only 17 genes as an input list we would not expect
statistically significant enrichment of genes for any
category. Therefore, we caution against interpretation of
these GO categorizations in that sense.
Conclusions
While most breast cancers are diagnosed at a resect-
able and thus potentially curable stage, all carry some
risk of relapse. As such, most patients are in theory
candidates for adjuvant maneuvers to lessen the risk of
relapse. We present a meta-analysis of gene expression
data in 858 lymph-node-negative, ER-positive, HER2-
negative, chemotherapy-naive breast tumors from pub-
lished datasets. This dataset supports a method of
predicting the likelihood of long-term survival without
relapse for such breast cancers. The method involves
assaying the expression level of one or more RNA tran-
scripts or their expression products in a breast cancer
sample, from a set of eight or 17 genes each with one
or more alternate genes. We determine a RFRS and
risk group by applying the RFRS algorithm to tumor
derived gene expression. Furthermore, by comparing
the RFRS value to outcomes in training data we can
estimate a likelihood of long-term survival without
breast cancer relapse in a patient. In theory, those
breast cancer patients with tumors at high risk of re-
lapse could be treated more aggressively whereas those
at low risk of relapse could more safely avoid the risks
and side effects of systemic chemotherapy. The bene-
fits of this type of approach are expected to be signifi-
cant and are currently being evaluated in the TailorRX
(USA) and MINDACT (Europe) trials [31]. Our hope
is that this method, together with a rapid assay plat-
form could provide rapid (<1 h) and useful information
to inform clinical decision-making. A test developed
from this method could be applied to resected breast
tumor tissue (either frozen or fresh), formalin-fixed,
paraffin-embedded breast cancer tissue or tissue iso-
lated from a core biopsy or fine needle aspirate. We
also provide a list of reference genes for use in normal-
izing gene expression measurements if necessary.
We tested the hypothesis that a larger dataset with more
current clinical data would allow development of a signa-
ture with better performance than existing methods. Oursignature performed comparably but not significantly bet-
ter, perhaps suggesting that we have reached the upper
limits of accuracy for array-based transcriptional signatures
for recurrence in ER+/LN- breast cancer. However, RFRS
compares favorably to previously described, clinically avail-
able products that predict outcome in breast cancer (for ex-
ample, OncotypeDX and Mammaprint) in several respects:
(1) the signature was built from the largest training dataset
available to date; (2) patients with HER2+ tumors were ex-
cluded, thus focusing only on patients without an existing
clear treatment course; (3) the gene signature predicts re-
lapse with equal success for both patients that went on to
receive adjuvant hormonal therapy and those who did not;
(4) the gene signature was designed for robustness with (in
most cases) several alternate genes available for each
primary gene; (5) probe set sequences have been validated
by alignment and manual assessment. These features,
particularly the latter two, make this signature an especially
strong candidate for efficient migration to low-cost plat-
forms for use in a clinical setting. Development of a panel
for use in the clinic could take advantage of not only pri-
mary genes but also some number of alternate genes to in-
crease the chance of a successful migration. Given the
small but significant number of discrepancies observed be-
tween clinical and array-based determination of ER status
we also recommend inclusion of standard biomarkers such
as ER, PR, and HER2 on any design. We provide a list of
consistently expressed genes, specific to breast tumor tis-
sue, for use as control genes for those platforms that re-
quire them. Finally, we make available a large, carefully
curated gene expression dataset for ER+, LN- breast cancer
along with clinical annotations for use in the research
community.Additional files
Additional file 1: Contains all supplementary figures, tables, and a
more detailed explanation of all additional files.
Additional file 2: Contains clinical annotations for the 572 patients
in the training dataset.
Additional file 3: Contains clinical annotations for the 286 patients
in the test dataset.
Additional file 4: Contains GCRMA normalized mRNA expression
values for the 572 patients in the training dataset.
Additional file 5: Contains GCRMA normalized mRNA expression
values for the 286 patients in the test dataset.
Additional file 6: Describes alignment of the top 100 probe sets to
the reference genome.
Additional file 7: Contains actual probe sequences for the top 100
probe sets.
Additional file 8: Describes alignment of all reference probe sets to
the reference genome.
Additional file 9: Contains actual probe sequences for all reference
probe sets.
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input needed for RFRS sample code and provides sample R code
for running the RFRS algorithm.
Additional file 11: Consists of the R data files for 17-gene and
eight-gene models.
Additional file 12: Consists of additional R data files which allow
plotting of patients’ RFRS result and determination of predicted
relapse probability for the report file.
Additional file 13: Shows a sample patient report produced by the
algorithm.
Additional file 14: Consists of a complete list of GEO sample
identifiers for training and test datasets combined.
Additional file 15: Consists of additional sample R code to help
reproduce the analysis.
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